Promising myeloma combo trial halted early after only 2 patients
NCT ID NCT06351644
First seen Nov 12, 2025 · Last updated Apr 29, 2026 · Updated 20 times
Summary
This early-stage study tested a new oral drug called narazaciclib combined with dexamethasone in people with multiple myeloma that had returned or stopped responding to prior treatments. The goal was to find a safe and effective dose. However, the trial was terminated after enrolling only 2 participants, so no conclusions about safety or effectiveness could be drawn.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mount Sinai Health System
New York, New York, 10029, United States
Conditions
Explore the condition pages connected to this study.